AstraZeneca vs Broadcom: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AstraZeneca and Broadcom side by side

1. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

2. 1991Broadcom

   Broadcom Corporation founded

   UCLA professor Henry Samueli and his former doctoral student Henry Nicholas III found Broadcom Corporation in Los Angeles to build broadband communications chips in CMOS, starting with chips for cable modems and digital set-top boxes.

3. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

4. 1998Broadcom

   Broadcom Corporation IPO

   Broadcom Corporation lists on Nasdaq in April 1998 at $24 a share, as cable operators roll out DOCSIS cable modems built on its chips.

5. 1999AstraZeneca

   Astra and Zeneca Merge to Form AstraZeneca

   The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

6. 2000AstraZeneca

   Nexium Launch Replaces Prilosec

   AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

7. 2005Broadcom

   Avago Technologies formed

   KKR and Silver Lake buy Agilent Technologies' semiconductor products group, whose roots go back to Hewlett-Packard's chip operations, for about $2.66 billion and name it Avago Technologies.

8. 2006AstraZeneca

   Acquisition of Cambridge Antibody Technology

   AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

9. 2006Broadcom

   Hock Tan becomes CEO of Avago

   Hock Tan becomes president and CEO of Avago in March 2006 and begins pruning its portfolio to the businesses with defensible technology.

10. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

11. 2009Broadcom

    Avago lists on Nasdaq

    Avago Technologies goes public on Nasdaq in August 2009 at $15 a share, giving it stock to use in later acquisitions.

12. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

13. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

14. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

15. 2014Broadcom

    LSI Corporation acquired

    Avago completes its $6.6 billion purchase of LSI in May 2014, adding storage controllers and custom ASIC design teams.

16. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

17. 2016Broadcom

    Avago buys Broadcom Corporation

    Avago completes its $37 billion acquisition of Broadcom Corporation in February 2016, takes the Broadcom name and trades as AVGO.

18. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

19. 2017Broadcom

    Brocade acquired

    Broadcom completes its $5.9 billion purchase of Brocade Communications in November 2017, adding Fibre Channel storage networking switches.

20. 2018Broadcom

    Qualcomm bid blocked and move to the U.S.

    President Trump blocks Broadcom's unsolicited bid for Qualcomm on national security grounds in March 2018. Broadcom completes its redomicile from Singapore to the United States that April.

21. 2018Broadcom

    CA Technologies acquired

    Broadcom completes its $18.9 billion purchase of CA Technologies in November 2018, its first large software deal, creating the infrastructure software segment.

22. 2019Broadcom

    Symantec enterprise security acquired

    Broadcom buys Symantec's enterprise security business for $10.7 billion in November 2019, adding endpoint, web and data loss prevention software.

23. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

24. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

25. 2022Broadcom

    VMware deal announced

    Broadcom agrees in May 2022 to buy VMware in a cash-and-stock deal valued at about $61 billion at announcement.

26. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

27. 2023Broadcom

    VMware acquisition closes

    Broadcom completes the VMware acquisition on 22 November 2023 after clearances in the U.S., EU, UK and China, a deal valued at about $69 billion including assumed debt.

28. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

29. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

30. 2024Broadcom

    Stock split and $1 trillion market value

    Broadcom splits its stock 10-for-1 in July 2024, sells VMware's end-user computing unit to KKR for about $4 billion, reports fiscal 2024 revenue of $51.6 billion and passes $1 trillion in market value in December 2024.

31. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

32. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

33. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

34. 2025Broadcom

    OpenAI partnership and record fiscal 2025

    OpenAI and Broadcom agree in October 2025 to deploy 10 gigawatts of OpenAI-designed accelerators. Fiscal 2025 revenue rises 24% to $63.9 billion, with about $20 billion from AI chips.

35. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

36. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

37. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

38. 2026Broadcom

    AI chips pass half of revenue

    Amie Thuener becomes CFO in June 2026. Third-quarter fiscal 2026 revenue rises 86% to $29.6 billion, and AI semiconductor revenue of $16.7 billion is 56% of the total.

Acquisitions

Questions about AstraZeneca vs Broadcom